Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115679) titled 'A single-arm, single-center clinical study of toripalimab as adjuvant therapy for high-risk clear cell renal cell carcinoma after radical nephrectomy' on Dec. 30, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University
Condition:
Renal clear cell carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-30
Target Sample Size: Experimental group:100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=298603
Published by HT Digital Content ...